<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-37707" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Febuxostat</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gerriets</surname>
            <given-names>Valerie</given-names>
          </name>
          <aff>California Northstate University College of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jialal</surname>
            <given-names>Ishwarlal</given-names>
          </name>
          <aff>VA MEDICAL CENTER, MATHER , CA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Valerie Gerriets declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ishwarlal Jialal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-37707.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">An educational&#x000a0;discussion of managing hyperuricemia conditions,&#x000a0;including gout, is essential for healthcare providers. This session&#x000a0;addresses the indications, mechanism of action, administration guidelines, adverse event profile, contraindications, and monitoring strategies for febuxostat, a xanthine oxidase inhibitor. Given recent FDA recommendations regarding cardiovascular risks associated with febuxostat compared to allopurinol, understanding when to opt for febuxostat over allopurinol is crucial. Furthermore,&#x000a0;understanding&#x000a0;febuxostat's pharmacology empowers healthcare professionals to tailor treatment plans to individual patient needs, optimizing therapeutic efficacy while minimizing potential adverse effects. By integrating dosing considerations, pharmacokinetic insights, toxicity profiles, and pertinent drug interactions, healthcare providers can make informed decisions to enhance patient care outcomes in managing gout and related conditions.</p>
        <p>This activity facilitates an in-depth exploration of febuxostat's role within the therapeutic landscape, fostering a holistic understanding of its clinical utility and challenges. This session enhances a clinician's ability to navigate febuxostat therapy effectively by equipping healthcare professionals with the requisite knowledge and skills. Through proactive monitoring and thoughtful consideration of patient-specific factors, healthcare providers can mitigate risks and maximize benefits associated with febuxostat treatment, ultimately improving outcomes for individuals with gout or hyperuricemia.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of febuxostat.</p></list-item><list-item><p>Evaluate&#x000a0;the adverse effects of febuxostat.</p></list-item><list-item><p>Determine&#x000a0;the appropriate monitoring strategies for patients taking febuxostat.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from&#x000a0;febuxostat&#x000a0;therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=37707&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=37707">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-37707.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Febuxostat received approval from the Food and Drug Administration (FDA) in 2009.<xref ref-type="bibr" rid="article-37707.r1">[1]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Febuxostat is a non-purine selective inhibitor of the enzyme xanthine oxidase and is FDA-approved for the chronic management of hyperuricemia in patients diagnosed with gout.<xref ref-type="bibr" rid="article-37707.r2">[2]</xref><xref ref-type="bibr" rid="article-37707.r3">[3]</xref>&#x000a0;Due to an increased risk of cardiovascular mortality with febuxostat versus allopurinol, the FDA recently recommended limiting the use of febuxostat to patients for whom allopurinol is not&#x000a0;effective or who experience severe&#x000a0;adverse effects with allopurinol. Febuxostat is not approved for treating&#x000a0;asymptomatic hyperuricemia.<xref ref-type="bibr" rid="article-37707.r4">[4]</xref>&#x000a0;</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Febuxostat demonstrates efficacy in&#x000a0;hyperuricemia&#x000a0;as part of tumor lysis syndrome, especially when allopurinol is contraindicated.<xref ref-type="bibr" rid="article-37707.r5">[5]</xref><xref ref-type="bibr" rid="article-37707.r6">[6]</xref></p>
      </sec>
      <sec id="article-37707.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Febuxostat is a non-purine selective inhibitor of the enzyme xanthine oxidase, which is involved in purine catabolism.<xref ref-type="bibr" rid="article-37707.r7">[7]</xref> The xanthine oxidase enzyme catalyzes&#x000a0;2 reactions that ultimately generate uric acid from hypoxanthine. Febuxostat forms a stable complex with both the reduced and oxidized form of the enzyme, inhibiting its function. Treatment with febuxostat lowers serum uric acid levels in animals and humans.<xref ref-type="bibr" rid="article-37707.r8">[8]</xref> The therapeutic effect of febuxostat involves lowering serum uric acid levels in patients with hyperuricemia, defined by the uric acid serum concentration that exceeds the solubility of uric acid (approximately 7 mg/dL).<xref ref-type="bibr" rid="article-37707.r9">[9]</xref><xref ref-type="bibr" rid="article-37707.r10">[10]</xref> The chemical structure of febuxostat does not resemble either purines or pyrimidine structures, and it does not appear to inhibit other enzymes in the nucleotide catabolic pathways.<xref ref-type="bibr" rid="article-37707.r11">[11]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:&#x000a0;</bold>Febuxostat is rapidly absorbed with peak&#x000a0;plasma concentrations (Cmax) attained&#x000a0;after 1 to 1.5 hours of oral administration.&#x000a0;Approximately&#x000a0;49% of the orally administered dose of febuxostat is absorbed.<xref ref-type="bibr" rid="article-37707.r12">[12]</xref>&#x000a0;</p>
        <p><bold>Distribution: </bold>The steady-state volume of distribution of febuxostat is&#x000a0;approximately 50 L.&#x000a0;Febuxostat&#x000a0;has&#x000a0;high plasma protein binding (PPB) and binds primarily to albumin. The&#x000a0;PPB of febuxostat is approximately 99%.<xref ref-type="bibr" rid="article-37707.r13">[13]</xref></p>
        <p><bold>Metabolism: </bold>Febuxostat is metabolized by conjugation via UGT (uridine diphosphate glucuronosyltransferase) enzymes, including UGT1A1,&#x000a0;UGT1A3, UGT1A9, and UGT2B7. Febuxostat is metabolized by&#x000a0;CYPs1A2, CYP2C8, CYP2C9, and non-CYP enzymes. Febuxostat also inhibits&#x000a0;breast cancer resistance protein (BCRP) activity.<xref ref-type="bibr" rid="article-37707.r14">[14]</xref></p>
        <p><bold>Excretion: </bold>Febuxostat's apparent mean elimination half-life (t<sub>1/2</sub>) is&#x000a0;approximately 5 to 8 hours. Metabolites of febuxostat are eliminated by both hepatic and renal routes. The percentage of febuxostat excreted unchanged in the urine is less than 5%.<xref ref-type="bibr" rid="article-37707.r15">[15]</xref></p>
      </sec>
      <sec id="article-37707.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths&#x000a0;</bold>
</p>
        <p>Febuxostat is available in both 40 mg and 80 mg tablet formulations.&#x000a0;</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Febuxostat is administered orally with an initial dose of 40 mg/d.<xref ref-type="bibr" rid="article-37707.r12">[12]</xref>&#x000a0;This drug can be administered without regard to food.&#x000a0;The clinician can increase the dose of febuxostat to 80 mg daily in patients who do not achieve a serum uric acid level of less than 6 mg/dL after&#x000a0;2 weeks of treatment with 40 mg. Upon initiating treatment with febuxostat, gout flares may occur.<xref ref-type="bibr" rid="article-37707.r16">[16]</xref>&#x000a0;Therefore, flare prophylaxis with either a non-steroidal anti-inflammatory drug (NSAID) or colchicine is recommended concurrently with febuxostat treatment and may continue for up to&#x000a0;6 months.<xref ref-type="bibr" rid="article-37707.r17">[17]</xref><xref ref-type="bibr" rid="article-37707.r18">[18]</xref>&#x000a0;The safety&#x000a0;and&#x000a0;efficacy of febuxostat&#x000a0;in the pediatric&#x000a0;age group have not been demonstrated. The American College of Rheumatology 2020 guidelines state that&#x000a0;urate-lowering therapy (with febuxostat/allopurinol) is conditionally suggested for patients with moderate-to-severe CKD (stage &#x02265;3),&#x000a0;urolithiasis or serum uric acid concentration &#x0003e;9 mg/dL.<xref ref-type="bibr" rid="article-37707.r19">[19]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>No dose adjustment is necessary for mild (Child-Pugh Class A) or&#x000a0;moderate hepatic impairment (Child-Pugh Class B) in patients receiving febuxostat therapy. No clinical studies have been performed in patients with severe hepatic impairment&#x000a0;(Child-Pugh Class C). Use with extreme caution.</p>
        <p><bold><bold>Renal impairment:</bold></bold><bold>&#x000a0;</bold>No dosage adjustment of febuxostat is necessary for mild or moderate renal impairment (CrCl&#x000a0;30 to 89 mL/min). In patients with severe renal impairment (CrCl &#x0003c;30 mL/min), the dose of febuxostat tablets is reduced to 40 mg once daily. American College of Rheumatology guidelines recommend febuxostat for patients with moderate to severe CKD.<xref ref-type="bibr" rid="article-37707.r19">[19]</xref></p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Gout is rare in reproductive-age females due to the uricosuric effects of estrogen. In pregnant women, gout is quite uncommon.&#x000a0;In preclinical studies, neonatal mortality&#x000a0;has been&#x000a0;observed at approximately 40 times the MRHD (maximum recommended human dose). Use with caution. Pharmacological&#x000a0;management&#x000a0;should be based on risk-benefit assessments.<xref ref-type="bibr" rid="article-37707.r20">[20]</xref></p>
        <p><bold><bold><bold>Breastfeeding considerations:&#x000a0;</bold></bold></bold>No clinical information is available on using febuxostat during lactation. Hypothetically, febuxostat is more than 99% bound to plasma proteins; consequently, the concentration of febuxostat in maternal milk is likely to be low. Additionally, the oral bioavailability of febuxostat is only about 50%, so the amount an infant receives systemically is expected to be very small. However, febuxostat is present in rat milk. Hence, the risk-benefit analysis is crucial before administering a febuxostat to a nursing mother. An alternative agent, allopurinol, should be considered during lactation.<xref ref-type="bibr" rid="article-37707.r21">[21]</xref></p>
        <p><bold>Pediatric patients</bold>:&#x000a0;Febuxostat's safety and efficacy have not been confirmed in the pediatric population.</p>
        <p><bold>Older patients:</bold> No dose adjustment is required in&#x000a0;older patients. While there were no considerable variations in safety or efficacy across different age groups, some older individuals might exhibit increased sensitivity to the febuxostat.</p>
        <p><bold>Secondary hyperuricemia:</bold>&#x000a0;Febuxostat is not FDA-approved&#x000a0;for individuals with markedly increased urate formation rates, such as those with malignant disease or undergoing treatment and those with Lesch-Nyhan syndrome. In rare instances,&#x000a0;increased urine xanthine levels may&#x000a0;lead to&#x000a0;urinary tract deposition.</p>
      </sec>
      <sec id="article-37707.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Liver function abnormalities, dizziness, arthralgia, nausea, and rash have been known to occur in more than 1% of patients, based on&#x000a0;multiple randomized, controlled clinical studies ranging in length from 6 to 12 months.<xref ref-type="bibr" rid="article-37707.r16">[16]</xref></p>
        <p>Less common adverse effects are listed below by organ system. Based on multiple randomized controlled clinical trials, these occur in less than 1% of the febuxostat-treated group.<xref ref-type="bibr" rid="article-37707.r22">[22]</xref><xref ref-type="bibr" rid="article-37707.r23">[23]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Blood and lymphatic system: Anemia, idiopathic thrombocytopenic purpura, leukocytosis/leukopenia, neutropenia, pancytopenia, splenomegaly, thrombocytopenia</p>
          </list-item>
          <list-item>
            <p>Cardiac: Angina pectoris, atrial fibrillation/flutter, cardiac murmur, EKG abnormal, palpitations, sinus bradycardia, tachycardia</p>
          </list-item>
          <list-item>
            <p>Ear and eye: Deafness, tinnitus, vertigo, blurred vision</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal: Abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting</p>
          </list-item>
          <list-item>
            <p>Immune: Hypersensitivity reactions</p>
          </list-item>
          <list-item>
            <p>Infections: Herpes zoster</p>
          </list-item>
          <list-item>
            <p>Metabolism-related: Anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decrease/increase</p>
          </list-item>
          <list-item>
            <p>Musculoskeletal: Arthritis, joint stiffness, joint swelling, muscle spasms, twitching, weakness, musculoskeletal pain/stiffness, myalgia</p>
          </list-item>
          <list-item>
            <p>Nervous system: Altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor</p>
          </list-item>
          <list-item>
            <p>Psychiatric: Agitation, anxiety, depression, insomnia, irritability, decreased libido, nervousness, panic attack, personality change</p>
          </list-item>
          <list-item>
            <p>Renal: Hematuria, nephrolithiasis, pollakiuria, proteinuria, renal failure, renal insufficiency, urgency, incontinence</p>
          </list-item>
          <list-item>
            <p>Reproductive: Breast pain, erectile dysfunction, gynecomastia</p>
          </list-item>
          <list-item>
            <p>Respiratory: Bronchitis, cough, dyspnea, epistaxis, nasal dryness, paranasal sinus hypersecretion, pharyngeal edema, respiratory tract congestion, sneezing, throat irritation, upper respiratory tract infection</p>
          </list-item>
          <list-item>
            <p>Skin and subcutaneous tissue: Alopecia, angioedema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, abnormal hair growth, hyperhidrosis, peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria</p>
          </list-item>
          <list-item>
            <p>Vascular: Flushing, hot flush, hypertension, hypotension</p>
          </list-item>
          <list-item>
            <p>Altered laboratory parameters include:
<list list-type="bullet"><list-item><p>Prolonged activated partial thromboplastin and prothrombin time</p></list-item><list-item><p>Abnormal EEG</p></list-item><list-item><p>Elevated
<list list-type="bullet"><list-item><p>Creatinine</p></list-item><list-item><p>Sodium</p></list-item><list-item><p>Glucose</p></list-item><list-item><p>Cholesterol</p></list-item><list-item><p>Triglycerides</p></list-item><list-item><p>Amylase</p></list-item><list-item><p>Potassium</p></list-item><list-item><p>TSH</p></list-item><list-item><p>MCV</p></list-item><list-item><p>BUN/Cr</p></list-item><list-item><p>Creatine phosphokinase (CPK)</p></list-item><list-item><p>LDH</p></list-item><list-item><p>PSA</p></list-item><list-item><p>Low-density lipoprotein (LDL)</p></list-item></list>
</p></list-item><list-item><p>Reduced
<list list-type="bullet"><list-item><p>Bicarbonate</p></list-item><list-item><p>Platelet count</p></list-item><list-item><p>RBC</p></list-item><list-item><p>Hematocrit &#x00026; hemoglobin</p></list-item><list-item><p>Lymphocyte count</p></list-item><list-item><p>Neutrophil count</p></list-item></list>
</p></list-item><list-item><p>Urinary casts</p></list-item><list-item><p>Urine positive for white blood cells and protein</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Antacids: Antacids such as magnesium hydroxide and aluminum hydroxide delay absorption by approximately 1 hour, but the extent of absorption is not affected.&#x000a0;Therefore,&#x000a0;febuxostat may be&#x000a0;administered without regard to antacid use.<xref ref-type="bibr" rid="article-37707.r13">[13]</xref></p>
        <p>Theophylline: The administration of&#x000a0;febuxostat&#x000a0;with theophylline&#x000a0;increases its concentration and absorption. These differences were not deemed statistically significant in the study. However, there was a 400-fold increase in 1-methylxanthine (a metabolite of theophylline) excreted in urine due to xanthine oxidase inhibition by febuxostat. The safety of chronic long-term exposure to 1-methylxanthine has not been assessed. Caution is advised when febuxostat is administered with theophylline.<xref ref-type="bibr" rid="article-37707.r24">[24]</xref></p>
        <p>Repaglinide: Concurrent administration of repaglinide with febuxostat can cause severe hypoglycemia. Febuxostat inhibits CYP2C8, resulting in delayed&#x000a0;elimination and increased concentration of&#x000a0;repaglinide.<xref ref-type="bibr" rid="article-37707.r25">[25]</xref></p>
        <p>Methotrexate: Febuxostat inhibits the breast cancer resistance protein (BCRP), and concomitant administration of febuxostat&#x000a0;increases&#x000a0;methotrexate-induced&#x000a0;hepatotoxicity by inhibiting hepatic BCRP.<xref ref-type="bibr" rid="article-37707.r14">[14]</xref></p>
        <p>Rosuvastatin: Rosuvastatin is a BCRP substrate; febuxostat increases rosuvastatin exposure by inhibiting its BCRP-mediated efflux in the small intestine.<xref ref-type="bibr" rid="article-37707.r26">[26]</xref></p>
      </sec>
      <sec id="article-37707.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Febuxostat contraindications include patients treated with azathioprine or mercaptopurine. Xanthine oxidase inhibition&#x000a0;increases concentrations of azathioprine and mercaptopurine, resulting in&#x000a0;serious toxicity&#x000a0;that can cause myelosuppression.<xref ref-type="bibr" rid="article-37707.r12">[12]</xref>&#x000a0;Febuxostat's formulation contains&#x000a0;lactose as an excipient. Use with caution for patients who are lactose-intolerant.<xref ref-type="bibr" rid="article-37707.r27">[27]</xref></p>
        <p>
<bold>Box Warning</bold>
</p>
        <p><bold>Cardiovascular events:&#x000a0;</bold>In randomized controlled studies, there was a higher rate of cardiovascular deaths and non-fatal myocardial infarctions and strokes in the febuxostat-treated group compared with the allopurinol-treated group. Based on this new information, the FDA is&#x000a0;limiting the use of febuxostat to&#x000a0;patients for which allopurinol is not efficacious&#x000a0;or patients who experience severe&#x000a0;adverse&#x000a0;effects with allopurinol, and there is now a boxed warning of cardiovascular death.<xref ref-type="bibr" rid="article-37707.r4">[4]</xref>&#x000a0;In patients using febuxostat with a previous&#x000a0;history of cardiovascular disease (CVD) or encountering a new cardiovascular event, the American College of Rheumatology (ACR) suggests considering a transition to another urate-lowering therapy (ULT) agent.<xref ref-type="bibr" rid="article-37707.r19">[19]</xref></p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p><bold>Gout Flares:&#x000a0;</bold>An increase in gout flares frequently occurs after initiating febuxostat.<xref ref-type="bibr" rid="article-37707.r16">[16]</xref> This increase is likely due to reduced serum uric acid levels, which mobilize the urate crystals in tissue deposits. Therefore, flare prophylaxis with either a non-steroidal anti-inflammatory drug (NSAID) or colchicine is recommended concurrently with febuxostat treatment and may continue for up to&#x000a0;6 months. Febuxostat should not be used to treat secondary hyperuricemia or asymptomatic hyperuricemia.</p>
        <p><bold>Hepatotoxicity:&#x000a0;</bold>In randomized controlled studies, liver function abnormalities were reported, including transaminase elevations greater than&#x000a0;3 times the normal upper limit.<xref ref-type="bibr" rid="article-37707.r28">[28]</xref><xref ref-type="bibr" rid="article-37707.r16">[16]</xref><bold>&#x000a0;</bold>Although this effect has not been demonstrated to be clinically significant, recommendations include a baseline liver test panel (including serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and total bilirubin) before initiating febuxostat treatment. A liver panel is also recommended periodically during treatment and in patients experiencing any signs of hepatic injury.<xref ref-type="bibr" rid="article-37707.r29">[29]</xref>&#x000a0;The case report highlights&#x000a0;2 instances of febuxostat-induced acute liver injury in patients who are hospitalized with heart failure. While rare, this form of drug-induced liver injury presents challenges for clinicians. Both patients had heart failure with reduced ejection fraction, prompting further investigation into whether heart failure may be a risk factor for febuxostat-related liver injury. This emphasizes the importance of regular liver function monitoring, especially in patients with heart failure, during febuxostat treatment.<xref ref-type="bibr" rid="article-37707.r30">[30]</xref></p>
        <p><bold><bold>Severe cutaneous adverse reaction (SCAR):&#x000a0;</bold></bold>Severe hypersensitivity reactions, including Stevens-Johnson Syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia &#x00026; systemic symptoms (DRESS), have been attributed to febuxostat. Discontinue&#x000a0;febuxostat&#x000a0;if severe skin reactions are suspected and&#x000a0;initiate&#x000a0;prompt&#x000a0;treatment.<xref ref-type="bibr" rid="article-37707.r31">[31]</xref><xref ref-type="bibr" rid="article-37707.r32">[32]</xref></p>
      </sec>
      <sec id="article-37707.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patient monitoring should include signs and symptoms of MI, stroke, and liver injury, as described in the warnings and precautions section.<xref ref-type="bibr" rid="article-37707.r4">[4]</xref>&#x000a0;Patients with impaired renal function appear to tolerate febuxostat well,&#x000a0;and dose adjustments are only required for severe renal impairment. Febuxostat may&#x000a0;delay the progression of chronic kidney disease.<xref ref-type="bibr" rid="article-37707.r33">[33]</xref><xref ref-type="bibr" rid="article-37707.r11">[11]</xref><xref ref-type="bibr" rid="article-37707.r34">[34]</xref></p>
        <p>A treat-to-target management strategy includes urate-lowering therapy (febuxostat/allopurinol) dosing directed by serial serum urate measurements to accomplish a target serum urate&#x000a0;is recommended over a fixed-dose drug strategy. Per ACR 2020 guidelines, serum urate levels should be monitored, and the dose of febuxostat should be adjusted to maintain the serum urate target of &#x0003c;6 mg/dL.<xref ref-type="bibr" rid="article-37707.r19">[19]</xref></p>
        <p>A lower&#x000a0;serum urate target&#x000a0;(&#x0003c;5 mg/dL) helps promote the rapid&#x000a0;dissolution of crystals.&#x000a0;Recommendations&#x000a0;for patients with severe gout&#x000a0;include reducing serum urate level until&#x000a0;total crystal dissolution and resolution of gout, according to EULAR (European Alliance of Associations for Rheumatology) guidelines.<xref ref-type="bibr" rid="article-37707.r10">[10]</xref></p>
      </sec>
      <sec id="article-37707.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There is no known human toxicity with febuxostat treatment. Febuxostat was evaluated in healthy patients in doses of up to 300 mg daily for&#x000a0;7 days without evidence of dose-limiting toxicities. Patients who overdose should be given symptomatic and supportive care.<xref ref-type="bibr" rid="article-37707.r7">[7]</xref></p>
      </sec>
      <sec id="article-37707.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Gout is the most common form of inflammatory arthritis, characterized by painful episodes of arthritis; gout results in substantial morbidity and disability.<xref ref-type="bibr" rid="article-37707.r35">[35]</xref>&#x000a0;Interprofessional communication and teamwork are necessary for the administration&#x000a0;and monitoring of febuxostat for effective management of gout. With the recent revisions of the FDA guidelines, physicians, nurses, and pharmacists must be particularly aware of current prescribing information.<xref ref-type="bibr" rid="article-37707.r4">[4]</xref></p>
        <p>As of early 2019, febuxostat is now recommended only for patients with gout who cannot tolerate&#x000a0;allopurinol or if allopurinol lacks efficacy; this is particularly pertinent in patients with cardiovascular disease.<xref ref-type="bibr" rid="article-37707.r36">[36]</xref> Pharmacists should familiarize themselves with the patient's gout medication history and verify that febuxostat is appropriate. They can also confirm dosing and perform medication reconciliation, alerting the patient's clinician to any concerns or potential interactions. Nurses can assess treatment efficacy and patient compliance, look for&#x000a0;adverse drug reactions&#x000a0;to medication, and report any concerns to the treating physician. All healthcare providers should educate patients regarding lifestyle modifications such as limiting alcohol, purine, and high fructose corn syrup intake.&#x000a0;The interprofessional healthcare team, consisting of clinicians, specialists including rheumatologists, specialty-trained nurses, and pharmacists, must work together to ensure that proper dosing and dispensing protocols are in place and be aware of the possibility of adverse effects, which includes informing the patient of the increased risk of gout flares upon treatment with febuxostat and treating the flares appropriately.<xref ref-type="bibr" rid="article-37707.r16">[16]</xref>&#x000a0;</p>
        <p>The relationship between febuxostat and cardiovascular disease remains controversial due to challenges in comparing trials and heterogeneous outcomes.&#x000a0;A systematic review of 20 randomized controlled trials found reassuring cardiovascular safety outcomes in&#x000a0;patients with gout who are treated with febuxostat compared to allopurinol. However, further research is needed to conclude patients with severe cardiovascular disease.<xref ref-type="bibr" rid="article-37707.r37">[37]</xref></p>
        <p>Delivering an augmented protocol of&#x000a0;urate-lowering therapy&#x000a0;by a team of clinicians, pharmacists, and nursing-led interventions to improve the treat-to-target strategy that includes patient education and shared decision-making can optimize the patient outcomes related to febuxostat therapy.<xref ref-type="bibr" rid="article-37707.r38">[38]</xref><xref ref-type="bibr" rid="article-37707.r19">[19]</xref><xref ref-type="bibr" rid="article-37707.r35">[35]</xref></p>
      </sec>
      <sec id="article-37707.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=37707&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=37707">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/37707/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=37707">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-37707.s11">
        <title>References</title>
        <ref id="article-37707.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robinson</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Febuxostat for the treatment of hyperuricaemia in gout.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>19</volume>
            <issue>11</issue>
            <fpage>1289</fpage>
            <page-range>1289-1299</page-range>
            <pub-id pub-id-type="pmid">30024787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <article-title>Febuxostat (Uloric) for chronic treatment of gout.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2009</year>
            <month>May</month>
            <day>18</day>
            <volume>51</volume>
            <issue>1312</issue>
            <fpage>37</fpage>
            <page-range>37-8</page-range>
            <pub-id pub-id-type="pmid">19448587</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takano</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hase-Aoki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Horiuchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kasahara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kondo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.</article-title>
            <source>Life Sci</source>
            <year>2005</year>
            <month>Mar</month>
            <day>04</day>
            <volume>76</volume>
            <issue>16</issue>
            <fpage>1835</fpage>
            <page-range>1835-47</page-range>
            <pub-id pub-id-type="pmid">15698861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Saag</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Borer</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Gorelick</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Whelton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Castillo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gunawardhana</surname>
                <given-names>L</given-names>
              </name>
              <collab>CARES Investigators</collab>
            </person-group>
            <article-title>Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Mar</month>
            <day>29</day>
            <volume>378</volume>
            <issue>13</issue>
            <fpage>1200</fpage>
            <page-range>1200-1210</page-range>
            <pub-id pub-id-type="pmid">29527974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alqurashi</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Tamim</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Alsubhi</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Alzahrani</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Tashkandi</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Tumor Lysis Syndrome in Patients With Solid Tumors: A Systematic Review of Reported Cases.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>10</issue>
            <fpage>e30652</fpage>
            <pub-id pub-id-type="pmid">36439565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McBride</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trifilio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baxter</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gregory</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Managing Tumor Lysis Syndrome in the Era of Novel Cancer Therapies.</article-title>
            <source>J Adv Pract Oncol</source>
            <year>2017</year>
            <season>Nov-Dec</season>
            <volume>8</volume>
            <issue>7</issue>
            <fpage>705</fpage>
            <page-range>705-720</page-range>
            <pub-id pub-id-type="pmid">30333933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khosravan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Grabowski</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Joseph-Ridge</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vernillet</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2006</year>
            <volume>45</volume>
            <issue>8</issue>
            <fpage>821</fpage>
            <page-range>821-41</page-range>
            <pub-id pub-id-type="pmid">16884320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Osada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tsuchimoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fukushima</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kondo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hasegawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Komoriya</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents.</article-title>
            <source>Eur J Pharmacol</source>
            <year>1993</year>
            <month>Sep</month>
            <day>14</day>
            <volume>241</volume>
            <issue>2-3</issue>
            <fpage>183</fpage>
            <page-range>183-8</page-range>
            <pub-id pub-id-type="pmid">8243554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Becker</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Lloyd</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lademacher</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.</article-title>
            <source>J Rheumatol</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>1273</fpage>
            <page-range>1273-82</page-range>
            <pub-id pub-id-type="pmid">19286847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richette</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Doherty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pascual</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barskova</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Becce</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Casta&#x000f1;eda-Sanabria</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Coyfish</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guillo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Janssens</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liot&#x000e9;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mallen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nuki</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perez-Ruiz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pimentao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Punzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pywell</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>So</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tausche</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Uhlig</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zavada</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Tubach</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bardin</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>2016 updated EULAR evidence-based recommendations for the management of gout.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>76</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-42</page-range>
            <pub-id pub-id-type="pmid">27457514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mayer</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Khosravan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vernillet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Joseph-Ridge</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mulford</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.</article-title>
            <source>Am J Ther</source>
            <year>2005</year>
            <season>Jan-Feb</season>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-34</page-range>
            <pub-id pub-id-type="pmid">15662289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gray</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Walters-Smith</surname>
                <given-names>NE</given-names>
              </name>
            </person-group>
            <article-title>Febuxostat for treatment of chronic gout.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2011</year>
            <month>Mar</month>
            <day>01</day>
            <volume>68</volume>
            <issue>5</issue>
            <fpage>389</fpage>
            <page-range>389-98</page-range>
            <pub-id pub-id-type="pmid">21330679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tomlinson</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Febuxostat in the management of hyperuricemia and chronic gout: a review.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>1209</fpage>
            <page-range>1209-20</page-range>
            <pub-id pub-id-type="pmid">19337428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ikemura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hiramatsu</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Shinogi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nakatani</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tawara</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Iwamoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Katayama</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Okuda</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein.</article-title>
            <source>Sci Rep</source>
            <year>2019</year>
            <month>Dec</month>
            <day>30</day>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>20359</fpage>
            <pub-id pub-id-type="pmid">31889141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edwards</surname>
                <given-names>NL</given-names>
              </name>
            </person-group>
            <article-title>Febuxostat: a new treatment for hyperuricaemia in gout.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2009</year>
            <month>May</month>
            <volume>48 Suppl 2</volume>
            <fpage>ii15</fpage>
            <page-range>ii15-ii19</page-range>
            <pub-id pub-id-type="pmid">19447778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bruce</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.</article-title>
            <source>Ann Pharmacother</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>40</volume>
            <issue>12</issue>
            <fpage>2187</fpage>
            <page-range>2187-94</page-range>
            <pub-id pub-id-type="pmid">17132810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schumacher</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Wortmann</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Macdonald</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Streit</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lademacher</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Joseph-Ridge</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.</article-title>
            <source>Arthritis Rheum</source>
            <year>2008</year>
            <month>Nov</month>
            <day>15</day>
            <volume>59</volume>
            <issue>11</issue>
            <fpage>1540</fpage>
            <page-range>1540-8</page-range>
            <pub-id pub-id-type="pmid">18975369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jackson</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>The efficacy and safety of febuxostat for urate lowering in gout patients &#x02265;65 years of age.</article-title>
            <source>BMC Geriatr</source>
            <year>2012</year>
            <month>Mar</month>
            <day>21</day>
            <volume>12</volume>
            <fpage>11</fpage>
            <pub-id pub-id-type="pmid">22436129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>FitzGerald</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mikuls</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Brignardello-Petersen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guyatt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Abeles</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gelber</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Harrold</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Libbey</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mount</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pillinger</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Sims</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Wenger</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Danve</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Lenert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Poon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Qasim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sehra</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>TSK</given-names>
              </name>
              <name>
                <surname>Toprover</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turgunbaev</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Neogi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>2020 American College of Rheumatology Guideline for the Management of Gout.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>72</volume>
            <issue>6</issue>
            <fpage>744</fpage>
            <page-range>744-760</page-range>
            <pub-id pub-id-type="pmid">32391934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pierre</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Canha</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Masri</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Gout in Pregnancy: A Rare Phenomenon.</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>Nov</month>
            <day>25</day>
            <volume>12</volume>
            <issue>11</issue>
            <fpage>e11697</fpage>
            <pub-id pub-id-type="pmid">33391930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r21">
          <label>21</label>
          <element-citation publication-type="book">
            <chapter-title>Febuxostat</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>11</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">34406726</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schumacher</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lloyd</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Lademacher</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>48</volume>
            <issue>2</issue>
            <fpage>188</fpage>
            <page-range>188-94</page-range>
            <pub-id pub-id-type="pmid">19141576</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Becker</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Espinoza</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lloyd</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lademacher</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.</article-title>
            <source>Arthritis Res Ther</source>
            <year>2010</year>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>R63</fpage>
            <pub-id pub-id-type="pmid">20370912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Gunawardhana</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Naik</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline.</article-title>
            <source>Int J Clin Pharmacol Ther</source>
            <year>2012</year>
            <month>May</month>
            <volume>50</volume>
            <issue>5</issue>
            <fpage>331</fpage>
            <page-range>331-7</page-range>
            <pub-id pub-id-type="pmid">22541837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Komatsu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Enomoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shiraishi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Morita</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nakayama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Funakoshi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hirano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Terada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miyamura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fujimoto</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Severe hypoglycemia caused by a small dose of repaglinide and concurrent use of nilotinib and febuxostat in a patient with type 2 diabetes.</article-title>
            <source>Diabetol Int</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>388</fpage>
            <page-range>388-392</page-range>
            <pub-id pub-id-type="pmid">33088647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lehtisalo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Keskitalo</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Tornio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lapatto-Reiniluoto</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jaatinen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Viinam&#x000e4;ki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Neuvonen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Backman</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Niemi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin.</article-title>
            <source>Clin Transl Sci</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>1236</fpage>
            <page-range>1236-1243</page-range>
            <pub-id pub-id-type="pmid">32453913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Rienzo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>D'Angelo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>D'Aversa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Campanale</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Cesario</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Montalto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gasbarrini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ojetti</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Lactose intolerance: from diagnosis to correct management.</article-title>
            <source>Eur Rev Med Pharmacol Sci</source>
            <year>2013</year>
            <volume>17 Suppl 2</volume>
            <fpage>18</fpage>
            <page-range>18-25</page-range>
            <pub-id pub-id-type="pmid">24443063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Becker</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Wortmann</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Eustace</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Palo</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Streit</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Joseph-Ridge</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Febuxostat compared with allopurinol in patients with hyperuricemia and gout.</article-title>
            <source>N Engl J Med</source>
            <year>2005</year>
            <month>Dec</month>
            <day>08</day>
            <volume>353</volume>
            <issue>23</issue>
            <fpage>2450</fpage>
            <page-range>2450-61</page-range>
            <pub-id pub-id-type="pmid">16339094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r29">
          <label>29</label>
          <element-citation publication-type="book">
            <chapter-title>Febuxostat</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>1</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">31643957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Two cases report of febuxostat-induced acute liver injury: acute heart failure as a probable risk factor?</article-title>
            <source>Drug Chem Toxicol</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-59</page-range>
            <pub-id pub-id-type="pmid">36789513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chou</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Febuxostat-associated drug reaction with eosinophilia and systemic symptoms (DRESS).</article-title>
            <source>J Clin Pharm Ther</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>689</fpage>
            <page-range>689-92</page-range>
            <pub-id pub-id-type="pmid">26365588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Febuxostat-Induced Toxic Epidermal Necrolysis.</article-title>
            <source>Am J Ther</source>
            <string-date>2022 Nov-Dec 01</string-date>
            <volume>29</volume>
            <issue>6</issue>
            <fpage>e710</fpage>
            <page-range>e710-e712</page-range>
            <pub-id pub-id-type="pmid">33021532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schumacher</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.</article-title>
            <source>Expert Opin Investig Drugs</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>14</volume>
            <issue>7</issue>
            <fpage>893</fpage>
            <page-range>893-903</page-range>
            <pub-id pub-id-type="pmid">16022578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeng</surname>
                <given-names>XX</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials: A PRISMA-compliant article.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>97</volume>
            <issue>13</issue>
            <fpage>e0161</fpage>
            <pub-id pub-id-type="pmid">29595642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mikuls</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Cheetham</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Rashid</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kerimian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Low</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Coburn</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Redden</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Saag</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial.</article-title>
            <source>Am J Med</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>132</volume>
            <issue>3</issue>
            <fpage>354</fpage>
            <page-range>354-361</page-range>
            <pub-id pub-id-type="pmid">30503879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deng</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>JX</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A&#x000a0;systematic review and meta-analysis.</article-title>
            <source>Clin Transl Sci</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>e13757</fpage>
            <pub-id pub-id-type="pmid">38488426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghossan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Aitisha Tabesh</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Fayad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Richette</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bardin</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular Safety of Febuxostat in Patients With Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials.</article-title>
            <source>J Clin Rheumatol</source>
            <year>2024</year>
            <month>Mar</month>
            <day>01</day>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>e46</fpage>
            <page-range>e46-e53</page-range>
            <pub-id pub-id-type="pmid">38115182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37707.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Geng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Association between patient adherence and treat-to-target in gout: A cross-sectional study.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2024</year>
            <month>Feb</month>
            <day>23</day>
            <volume>103</volume>
            <issue>8</issue>
            <fpage>e37228</fpage>
            <pub-id pub-id-type="pmid">38394537</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
